| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SCARA5 |
| Uniprot No | Q6ZMJ2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-495aa |
| 氨基酸序列 | MENKAMYLHTVSDCDTSSICEDSFDGRSLSKLNLCEDGPCHKRRASICCTQLGSLSALKHAVLGLYLLVFLILVGIFILAVSRPRSSPDDLKALTRNVNRLNESFRDLQLRLLQAPLQADLTEQVWKVQDALQNQSDSLLALAGAVQRLEGALWGLQAQAVQTEQAVALLRDRTGQQSDTAQLELYQLQVESNSSQLLLRRHAGLLDGLARRVGILGEELADVGGVLRGLNHSLSYDVALHRTRLQDLRVLVSNASEDTRRLRLAHVGMELQLKQELAMLNAVTEDLRLKDWEHSIALRNISLAKGPPGPKGDQGDEGKEGRPGIPGLPGLRGLPGERGTPGLPGPKGDDGKLGATGPMGMRGFKGDRGPKGEKGEKGDRAGDASGVEAPMMIRLVNGSGPHEGRVEVYHDRRWGTVCDDGWDKKDGDVVCRMLGFRGVEEVYRTARFGQGTGRIWMDDVACKGTEETIFRCSFSKWGVTNCGHAEDASVTCNRH |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SCARA5重组蛋白的示例参考文献(内容为示例，建议通过学术数据库核实具体研究)：
---
1. **文献名称**：*Structural and functional characterization of SCARA5 as a cell adhesion receptor*
**作者**：Li, X., et al.
**摘要**：研究通过重组表达SCARA5蛋白，解析其胞外结构域的三维构象，揭示其通过胶原样结构域介导细胞间黏附的分子机制，并验证其在胚胎发育中的潜在作用。
2. **文献名称**：*SCARA5 inhibits tumor metastasis via suppressing Wnt/β-catenin signaling in hepatocellular carcinoma*
**作者**：Wang, Y., et al.
**摘要**：利用重组SCARA5蛋白进行体外实验，证明其通过结合Wnt配体抑制β-catenin信号通路，从而抑制肝癌细胞迁移和侵袭，提出其作为肿瘤抑制因子的功能。
3. **文献名称**：*Recombinant SCARA5 binds to bacterial surface proteins and modulates innate immune response*
**作者**：Zhang, H., et al.
**摘要**：研究重组SCARA5与革兰氏阳性菌表面蛋白的相互作用，发现其通过激活巨噬细胞NF-κB通路增强抗菌免疫反应，为感染性疾病治疗提供新靶点。
4. **文献名称**：*Glycosylation analysis of recombinant SCARA5 and its role in ligand recognition*
**作者**：Chen, L., et al.
**摘要**：通过质谱分析重组SCARA5的糖基化修饰位点，证实其糖链结构对配体(如胶原IV)的结合特异性至关重要，并影响下游细胞信号传导。
---
建议通过PubMed或Web of Science检索关键词“SCARA5 recombinant protein”获取真实文献。
**Background of SCARA5 Recombinant Protein**
SCARA5 (Scavenger Receptor Class A Member 5) is a transmembrane glycoprotein belonging to the class A scavenger receptor family, known for its roles in innate immunity, cell adhesion, and homeostasis. Structurally, it contains a short cytoplasmic tail, a transmembrane domain, and an extracellular region with collagen-like and scavenger receptor cysteine-rich (SRCR) domains. These domains enable SCARA5 to interact with diverse ligands, including pathogen-associated molecular patterns (PAMPs), extracellular matrix components (e.g., laminin, collagen), and apoptotic cells, suggesting its involvement in immune surveillance and tissue remodeling.
SCARA5 is highly expressed in epithelial and endothelial cells, particularly in the liver, kidney, and placenta. Studies highlight its dual role in physiological and pathological contexts. In normal tissues, it supports cell adhesion and migration by binding to laminin, facilitating tissue integrity. However, in cancer, SCARA5 often exhibits downregulated expression, correlating with tumor progression and metastasis in hepatocellular carcinoma, breast cancer, and glioblastoma. This tumor-suppressive function is linked to its ability to inhibit Wnt/β-catenin and PI3K/Akt signaling pathways, reducing cell proliferation and invasion.
Recombinant SCARA5 protein is produced using mammalian or insect cell systems to ensure proper post-translational modifications, such as glycosylation, critical for ligand-binding activity. Purified SCARA5 is utilized in functional studies to explore its interactions, signaling mechanisms, and therapeutic potential. For instance, it serves as a tool to develop targeted therapies, including monoclonal antibodies or small-molecule inhibitors, to restore SCARA5 function in cancers or modulate immune responses. Additionally, its role in pathogen recognition positions it as a candidate for vaccine adjuvants or antimicrobial strategies.
Overall, SCARA5 recombinant protein bridges structural biology and translational research, offering insights into its multifaceted roles and paving the way for novel diagnostic and therapeutic applications.
在生物科技领域，蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者，凭借自身卓越的研发实力，每年能成功研发 1000 多种全新蛋白，在重组蛋白领域不断突破。 在重组蛋白生产过程中，艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白，到具有特定催化功能的酶、参与信号传导的激酶，再到用于免疫研究的病毒抗原，艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统，昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势，能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求，从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品，更是从源头到终端的一站式解决方案。从最初的基因合成，精准地构建出符合要求的基因序列，到载体构建，为蛋白表达创造适宜的环境，再到蛋白质表达和纯化，每一个环节都严格把控。我们充分尊重客户的个性化需求，在表达 / 纯化标签的选择、表达宿主的确定等方面，为客户量身定制专属方案。 同时，艾普蒂还配备了多种纯化体系，能够应对不同特性蛋白的纯化需求。这种灵活性和专业性，极大地提高了蛋白表达和纯化的成功率，让客户的研究项目得以顺利推进，在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台，包括： 哺乳动物细胞表达平台：利用哺乳动物细胞精准修饰蛋白，产出与天然蛋白相似的重组蛋白，用于药物研发、细胞治疗等。 杂交瘤开发平台：通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株，优化后的技术让抗体亲和力与特异性更高，应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台：FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞；Beacon® 基于微流控技术，单细胞水平捕获、分析 B 细胞，挖掘抗体多样性，缩短开发周期。 凭借这些平台，艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务，推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富，拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上，艾普蒂生物不仅经验老到，还积累了详实的成功案例。针对客户的工业化生产需求，我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节，对重组蛋白基因序列进行优化，全面探索多种条件，精准找出最契合客户需求的生产方法。 此外，公司还配备了自有下游验证平台，可对重组蛋白展开系统的质量检测与性能测试，涵盖蛋白互作检测、活性验证、内毒素验证等，全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发，确保生产出的蛋白质具备所需的纯度、稳定性与生物活性，这对于保障药物的安全性和有效性起着关键作用 ，与艾普蒂生物共同推动着行业的发展。
×
